Home › Funds › Privium Fund Management B.V. › AUTL
Privium Fund Management B.V. position in AUTL
AUTOLUS THERAPEUTICS LTD · Health Care
Privium Fund Management B.V. reported holding 469,490 shares of AUTL (AUTOLUS THERAPEUTICS LTD) in its Q3 2026 13F filing — a position valued at US$911K, representing 0.18% of its reported portfolio and ranking #41 among its reported holdings. Privium Fund Management B.V. has disclosed AUTL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Privium Fund Management B.V.'s AUTL position evolved
Privium Fund Management B.V. first disclosed a stake in AUTL in Q3 2023 at 34,967 shares (US$81K). The position peaked in Q3 2026 at 469,490 shares, worth US$911K. Across 13 filings, Privium Fund Management B.V. increased the stake 10 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 469,490 shares valued at US$911K — an increase of 106,060 shares quarter over quarter.. Notable position changes include a 43% increase in Q1 2024 (shares fell 45% over the following quarter), a 221% increase in Q2 2024 (shares rose 4% over the following quarter), a 29% increase in Q3 2026 (shares fell 40% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 34.97K | $81.47K | New |
| Q4 2023 | 34.97K | $239.17K | Hold |
| Q1 2024 | 50.06K | $319.37K | Add |
| Q2 2024 | 160.64K | $542.96K | Add |
| Q3 2024 | 185.64K | $673.87K | Add |
| Q4 2024 | 231.67K | $544.43K | Add |
| Q1 2025 | 251.67K | $390.09K | Add |
| Q2 2025 | 294.14K | $673.59K | Add |
| Q3 2025 | 308.84K | $503.40K | Add |
| Q4 2025 | 326.25K | $649.23K | Add |
| Q1 2026 | 363.43K | $501.53K | Add |
| Q2 2026 | 363.43K | $581.49K | Hold |
| Q3 2026 | 469.49K | $910.81K | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AUTL and 13F data
AUTL (AUTOLUS THERAPEUTICS LTD) is a Health Care company. 19 other funds we track also report a position in AUTL — the largest reported positions include MAK CAPITAL ONE LLC (US$53.8M), Syncona Portfolio Ltd (US$32.3M), ARMISTICE CAPITAL, LLC (US$24.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AUTL
- MAK CAPITAL ONE LLC 33.62M sh · $53.79M · Q2 2026
- Syncona Portfolio Ltd 16.64M sh · $32.28M · Q3 2026
- ARMISTICE CAPITAL, LLC 15.00M sh · $24.00M · Q2 2026
- Tetragon Partners GP Ltd 9.50M sh · $15.20M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.45M sh · $7.12M · Q2 2026
More on Privium Fund Management B.V.
FAQ
How long has Privium Fund Management B.V. held AUTL?
Privium Fund Management B.V. has disclosed AUTL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Privium Fund Management B.V.'s current position in AUTL?
As of Q3 2026, Privium Fund Management B.V. holds 469.49K shares of AUTL (AUTOLUS THERAPEUTICS LTD), valued at $910.81K, representing 0.18% of its reported portfolio and ranking #41.
Has Privium Fund Management B.V. been buying or selling AUTL?
In the latest 13F filing (Q3 2026), Privium Fund Management B.V. increased its position in AUTL. The position peaked in Q3 2026 at 469.49K shares.
Which other funds hold AUTL?
Other major institutional holders of AUTL include MAK CAPITAL ONE LLC, Syncona Portfolio Ltd, ARMISTICE CAPITAL, LLC, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.